Journal
BIOMEDICINES
Volume 9, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines9040341
Keywords
dexamethasone; drug conjugate; drug delivery system; gene delivery system; biopolymers
Ask authors/readers for more resources
Dexamethasone, a commonly prescribed glucocorticoid, shows a wide spectrum of pharmacological activity. Conjugating it to polymeric carriers helps reduce side effects on non-target organs and achieve controlled release in various target organs, making it potentially effective for anti-tumor therapy.
Dexamethasone (DEX) is the most commonly prescribed glucocorticoid (GC) and has a wide spectrum of pharmacological activity. However, steroid drugs like DEX can have severe side effects on non-target organs. One strategy to reduce these side effects is to develop targeted systems with the controlled release by conjugation to polymeric carriers. This review describes the methods available for the synthesis of DEX conjugates (carbodiimide chemistry, solid-phase synthesis, reversible addition fragmentation-chain transfer [RAFT] polymerization, click reactions, and 2-iminothiolane chemistry) and perspectives for their medical application as GC drug or gene delivery systems for anti-tumor therapy. Additionally, the review focuses on the development of DEX conjugates with different physical-chemical properties as successful delivery systems in the target organs such as eye, joint, kidney, and others. Finally, polymer conjugates with improved transfection activity in which DEX is used as a vector for gene delivery in the cell nucleus have been described.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available